Literature DB >> 20395939

Augmentation index and the evolution of aortic disease in marfan-like syndromes.

Kai Mortensen1, Johannes Baulmann, Meike Rybczynski, Sara Sheikhzadeh, Muhammet A Aydin, Henrik Treede, Ellen Dombrowski, Kristin Kühne, Philipp Peitsmeier, Christian R Habermann, Peter N Robinson, Manfred Stuhrmann, Jürgen Berger, Thomas Meinertz, Yskert von Kodolitsch.   

Abstract

BACKGROUND: The augmentation index at a heart rate of 75 beats/min (AIx@HR75) and central pulse pressure (CPP) can be measured noninvasively with applanation tonometry (APT). In this observational study, we investigated the relationship between AIx@HR75, CPP and aortic disease in patients with Marfan-like syndromes.
METHODS: We performed APT in 78 consecutive patients in whom classic Marfan syndrome (MFS) had been excluded (46 men and 32 women aged 34 +/- 13 years). These patients comprised 9 persons with MFS-like habitus, 6 with a bicuspid aortic valve (BAV), 5 with MASS phenotype, 3 with vascular type of Ehlers-Danlos syndrome (EDS), 3 with familial thoracic aortic aneurysm, 2 with Loeys-Dietz syndrome (LDS), 1 with mitral valve prolapse syndrome, 1 with familial ectopia lentis, and 48 persons with Marfan-like features but no defined syndrome. During 20 +/- 18 months after APT, we observed progression of aortic diameters in 15 patients, and aortic surgery or aortic dissection in 3 individuals.
RESULTS: All 11 patients with Marfan-like syndromes and progression of aortic disease exhibited AIx@HR75 > or =11%, including 8 individuals with aortic diameters < or =95th percentile of normal at baseline. Similarly, all 7 individuals without any defined syndrome but progression of aortic diameters exhibited AIx@HR75 >11%, including 6 individuals with aortic diameters < or =95th percentile at the time of APT. Aortic disease did not evolve at AIx@HR75 <11%. CPP is also related to aortic disease progression.
CONCLUSIONS: Aortic disease evolution relates to AIx@HR75 and CPP in Marfan like syndromes. Larger studies with comprehensive clinical and echocardiographic follow-up over long time intervals will be required to establish APT for prediction of aortic disease evolution in Marfan-like syndromes.

Entities:  

Mesh:

Year:  2010        PMID: 20395939     DOI: 10.1038/ajh.2010.78

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  5 in total

1.  Elevated Aortic Augmentation Index in Children Following Fontan Palliation: Evidence of Stiffer Arteries?

Authors:  Deepti P Bhat; Pooja Gupta; Sanjeev Aggarwal
Journal:  Pediatr Cardiol       Date:  2015-04-02       Impact factor: 1.655

Review 2.  Perspectives on the revised Ghent criteria for the diagnosis of Marfan syndrome.

Authors:  Yskert von Kodolitsch; Julie De Backer; Helke Schüler; Peter Bannas; Cyrus Behzadi; Alexander M Bernhardt; Mathias Hillebrand; Bettina Fuisting; Sara Sheikhzadeh; Meike Rybczynski; Tilo Kölbel; Klaus Püschel; Stefan Blankenberg; Peter N Robinson
Journal:  Appl Clin Genet       Date:  2015-06-16

3.  Mitral valve prolapse syndrome and MASS phenotype: Stability of aortic dilatation but progression of mitral valve prolapse.

Authors:  Moritz Rippe; Julie De Backer; Kerstin Kutsche; Laura Muiño Mosquera; Helke Schüler; Meike Rybczynski; Alexander M Bernhardt; Britta Keyser; Mathias Hillebrand; Thomas S Mir; Jürgen Berger; Stefan Blankenberg; Dietmar Koschyk; Yskert von Kodolitsch
Journal:  Int J Cardiol Heart Vasc       Date:  2016-01-21

4.  Augmentation index and aortic stiffness in bicuspid aortic valve patients with non-dilated proximal aortas.

Authors:  Patrick J Warner; Adeeb Al-Quthami; Erica L Brooks; Alyson Kelley-Hedgepeth; Eshan Patvardhan; Jeffrey T Kuvin; Kevin S Heffernan; Gordon S Huggins
Journal:  BMC Cardiovasc Disord       Date:  2013-03-15       Impact factor: 2.298

Review 5.  Pectus excavatum and heritable disorders of the connective tissue.

Authors:  Francesca Tocchioni; Marco Ghionzoli; Antonio Messineo; Paolo Romagnoli
Journal:  Pediatr Rep       Date:  2013-09-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.